Aileron Therapeutics Inc ALRN
We take great care to ensure that the data presented and summarized in this overview for AILERON THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALRN
View allLatest Institutional Activity in ALRN
Top Purchases
Top Sells
About ALRN
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Insider Transactions at ALRN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2024
|
James Brian Windsor President and CEO |
BUY
Open market or private purchase
|
Indirect |
400
+50.0%
|
$800
$2.25 P/Share
|
|
Jun 17
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,707
-0.27%
|
$14,121
$3.25 P/Share
|
|
Jun 14
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,900
-0.11%
|
$5,700
$3.3 P/Share
|
|
Jun 12
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
9,342
-0.27%
|
$28,026
$3.26 P/Share
|
|
Jun 11
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,752
-0.16%
|
$17,256
$3.3 P/Share
|
|
Jun 10
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
9,577
-0.54%
|
$28,731
$3.3 P/Share
|
|
Jun 07
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,740
-0.05%
|
$5,220
$3.28 P/Share
|
|
Jun 06
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,284
-0.12%
|
$12,852
$3.29 P/Share
|
|
Jun 05
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,291
-0.35%
|
$18,873
$3.3 P/Share
|
|
May 01
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
20,315
-0.07%
|
$81,260
$4.21 P/Share
|
|
Apr 30
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
90
-0.0%
|
$360
$4.98 P/Share
|
|
Apr 29
2024
|
University Of Texas > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
10,746
-0.1%
|
$42,984
$4.97 P/Share
|
|
Mar 05
2024
|
James Brian Windsor President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+21.93%
|
-
|
|
Dec 15
2023
|
James Brian Windsor President and CEO |
BUY
Open market or private purchase
|
Indirect |
225
+50.0%
|
$675
$3.37 P/Share
|
|
Nov 20
2023
|
James Brian Windsor President and CEO |
BUY
Open market or private purchase
|
Direct |
5,076
+49.77%
|
$5,076
$1.97 P/Share
|
|
Jan 08
2021
|
Muneer A Satter Director |
BUY
Open market or private purchase
|
Indirect |
9,000,000
+35.14%
|
$9,000,000
$1.1 P/Share
|
|
Apr 01
2019
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
20,610
-0.98%
|
$20,610
$1.9 P/Share
|
|
Mar 29
2019
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
106,540
-4.83%
|
$106,540
$1.85 P/Share
|
|
Mar 15
2019
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
43,800
-1.95%
|
$43,800
$1.92 P/Share
|
|
Mar 14
2019
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,800
-0.61%
|
$13,800
$1.88 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 2K shares |
|---|---|
| Open market or private purchase | 400 shares |
| Open market or private sale | 74.7K shares |
|---|